Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1968 1
1970 1
1971 2
1972 1
1975 3
1976 1
1977 2
1979 4
1980 3
1981 2
1982 4
1983 6
1984 5
1985 9
1986 5
1987 7
1988 6
1989 8
1990 13
1991 6
1992 16
1993 14
1994 15
1995 17
1996 21
1997 23
1998 18
1999 28
2000 24
2001 27
2002 35
2003 30
2004 24
2005 28
2006 30
2007 35
2008 39
2009 45
2010 46
2011 52
2012 74
2013 63
2014 81
2015 73
2016 58
2017 73
2018 58
2019 74
2020 92
2021 95
2022 93
2023 76
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,381 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Paragangliomas 6"
Page 1
Paraganglioma of the Head and Neck: A Review.
Sandow L, Thawani R, Kim MS, Heinrich MC. Sandow L, et al. Endocr Pract. 2023 Feb;29(2):141-147. doi: 10.1016/j.eprac.2022.10.002. Epub 2022 Oct 15. Endocr Pract. 2023. PMID: 36252779 Free PMC article. Review.
RESULTS: Paragangliomas (PGLs) are a group of neuroendocrine tumors that arise in the parasympathetic or sympathetic ganglia. Head and neck PGLs (HNPGLs) comprise 65% to 70% of all PGLs and account for 0.6% of all head and neck cancers. The majority of HNPGLs are be …
RESULTS: Paragangliomas (PGLs) are a group of neuroendocrine tumors that arise in the parasympathetic or sympathetic ganglia. Head an …
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Lenders JW, et al. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. J Clin Endocrinol Metab. 2014. PMID: 24893135
We recommend consideration of genetic testing in all patients, with testing by accredited laboratories. Patients with paraganglioma should be tested for SDHx mutations, and those with metastatic disease for SDHB mutations. ...We recommend minimally invasive adrenalectomy f …
We recommend consideration of genetic testing in all patients, with testing by accredited laboratories. Patients with paraganglioma s …
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M; Phaeochromocytoma Study Group in Japan. Kimura N, et al. Endocr Relat Cancer. 2014 May 6;21(3):405-14. doi: 10.1530/ERC-13-0494. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24521857
Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, histopathological criteria to discriminate malignant from benign tumours have not been established; therefore, reliable histopathological ma …
Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, …
Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, LiVolsi V, Krumeich L, Fraker DL, Nathanson KL, Cohen DL, Fishbein L. Wachtel H, et al. J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4661-70. doi: 10.1210/clinem/dgaa608. J Clin Endocrinol Metab. 2020. PMID: 32877928 Free PMC article.
PURPOSE: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP) are scoring systems to predict metastatic potential in pheochromocytomas (PCC) and paragangliomas (PGLs). ...RESULTS: …
PURPOSE: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paragangli …
Familial pheochromocytoma.
Erlic Z, Neumann HP. Erlic Z, et al. Hormones (Athens). 2009 Jan-Mar;8(1):29-38. doi: 10.14310/horm.2002.1219. Hormones (Athens). 2009. PMID: 19269919 Free article.
One third of patients with pheochromocytomas and paragangliomas are carriers of germline mutations in one of 6 genes and thus have a hereditary disorder. ...PGL syndromes have been genetically characterized as PGL 1, 3 and 4 and are caused by mutations in the succin …
One third of patients with pheochromocytomas and paragangliomas are carriers of germline mutations in one of 6 genes and thus …
Orbital Paraganglioma.
Zhu B, Yan J. Zhu B, et al. J Craniofac Surg. 2019 Sep;30(6):e503-e506. doi: 10.1097/SCS.0000000000005408. J Craniofac Surg. 2019. PMID: 30896513
BACKGROUND: Paragangliomas are groups of neuroendocrine neoplasms originating from neural crest cells throughout the body, but are rarely observed within the orbit. ...Subsequent histological and immunohistochemistry assays confirmed the diagnosis of orbital paraganglio …
BACKGROUND: Paragangliomas are groups of neuroendocrine neoplasms originating from neural crest cells throughout the body, but are ra …
Paragangliomas of the Spine.
Lv G, Lu L, Dai Z. Lv G, et al. Turk Neurosurg. 2017;27(3):401-407. doi: 10.5137/1019-5149.JTN.16276-15.1. Turk Neurosurg. 2017. PMID: 27593782 Free article.
AIM: Paragangliomas of the spine are rare tumors. Clinical presentations and courses of spinal paragangliomas are varied, and there are no standard principles of treatment to date. ...The follow-up period ranged from 40 to 98 months (mean, 72 months). Of the 6 …
AIM: Paragangliomas of the spine are rare tumors. Clinical presentations and courses of spinal paragangliomas are varied, and …
Head and neck paragangliomas.
Mendenhall WM, Amdur RJ, Vaysberg M, Mendenhall CM, Werning JW. Mendenhall WM, et al. Head Neck. 2011 Oct;33(10):1530-4. doi: 10.1002/hed.21524. Epub 2010 Nov 4. Head Neck. 2011. PMID: 21928426 Review.
BACKGROUND: The purpose of this study was to describe the natural history and optimal treatment for head and neck paragangliomas (PGs). METHODS: Our methods were the review of the pertinent literature. ...Approximately 90% are sporadic; the remainder are familial and relat …
BACKGROUND: The purpose of this study was to describe the natural history and optimal treatment for head and neck paragangliomas (PGs …
Management of primary cardiac paraganglioma.
Chan EY, Ali A, Umana JP, Nguyen DT, Hamilton DJ, Graviss EA, Ravi V, MacGillivray TE, Reardon MJ. Chan EY, et al. J Thorac Cardiovasc Surg. 2022 Jul;164(1):158-166.e1. doi: 10.1016/j.jtcvs.2020.09.100. Epub 2020 Oct 3. J Thorac Cardiovasc Surg. 2022. PMID: 33148444 Review.
OBJECTIVE: Cardiac paraganglioma is a rare tumor that most surgeons have limited experience treating. ...None of the patients had local recurrence of disease. There was 1 case of metastatic paraganglioma with death at 4 years postsurgery. Operative mortality was 10. …
OBJECTIVE: Cardiac paraganglioma is a rare tumor that most surgeons have limited experience treating. ...None of the patients had loc …
Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD.
Andrews KA, Ascher DB, Pires DEV, Barnes DR, Vialard L, Casey RT, Bradshaw N, Adlard J, Aylwin S, Brennan P, Brewer C, Cole T, Cook JA, Davidson R, Donaldson A, Fryer A, Greenhalgh L, Hodgson SV, Irving R, Lalloo F, McConachie M, McConnell VPM, Morrison PJ, Murday V, Park SM, Simpson HL, Snape K, Stewart S, Tomkins SE, Wallis Y, Izatt L, Goudie D, Lindsay RS, Perry CG, Woodward ER, Antoniou AC, Maher ER. Andrews KA, et al. J Med Genet. 2018 Jun;55(6):384-394. doi: 10.1136/jmedgenet-2017-105127. Epub 2018 Jan 31. J Med Genet. 2018. PMID: 29386252 Free PMC article.
BACKGROUND: Germline pathogenic variants in SDHB/SDHC/SDHD are the most frequent causes of inherited phaeochromocytomas/paragangliomas. Insufficient information regarding penetrance and phenotypic variability hinders optimum management of mutation carriers. ...METHODS: A r …
BACKGROUND: Germline pathogenic variants in SDHB/SDHC/SDHD are the most frequent causes of inherited phaeochromocytomas/paragangliomas …
1,381 results